Comparison of local and systemic inflammatory markers in patients with community-acquired pneumonia and pneumonia coexisting with lung cancer;Porównanie wybranych parametrów lokalnego i systemowego stanu zapalnego u chorych na pozaszpitalne zapalenie płuc i zapalenie płuc współistnieja̧ce z rakiem płuca

Pneumonologia i Alergologia Polska

Volumn 79, Issue 2, 2011, Pages 90-98

  Urbaniak, A ^a,b   Zieba M ^a   Zwolinska A ^c   Szkudlarek, U ^c   Luczynska M ^c   Noweta, K ^d   Kwiatkowska, S ^b  

^a Centrum Leczenia Chorób P uc i Rehabilitacji W Odzi   (Poland)

^b Medycznego w Łodzi ^*  (Poland)

^c Katedra Fizjologii Dowiadczalnej i Klinicznej Uniwersytetu   (Poland)

^d Klinika Pneumonologii i Alergologii Uniwersytetu   (Poland)

Author keywords

Hydrogen peroxide; Lung cancer; Pneumonia; Tumor necrosis factor alpha; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; HYDROGEN PEROXIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

AGED; ARTICLE; BLOOD; COMMUNICABLE DISEASE; COMPARATIVE STUDY; FEMALE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; OXIDATIVE STRESS; PNEUMONIA;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; HYDROGEN PEROXIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PNEUMONIA; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952321941     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Garcia-Vidal C., Calbo E., Pascual V., Ferrer C., Quintana S., Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur. Respir. J. 2007; 30: 951- -956. (Pubitemid 351194800)
2. Alvares-Lerma F., Torres A. Severe community-acquired pneumonia. Curr. Opin. Crit. Care 2004; 10: 369-374. (Pubitemid 39313506)
3. Garibaldi R.A. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am. J. Med. 1985; 78: 32-37. (Pubitemid 15036955)
4. Dehoux M.S., Boutten A., Ostinelli J. i wsp. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am. J. Respir. Crit. Care Med. 1994; 150: 710-716. (Pubitemid 24291499)
5. Schütte H., Lohmeyer J., Rosseau S. i wsp. Bronchoaleveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia, and cardiogenic pulmonary oedema. Eur. Respir. J. 1996; 9:1858-1867. (Pubitemid 26294756)
6. Majewska E., Kasielski M., Luczyński R., Bartosz G., Bia?asiewicz P., Nowak D. Elevated exhalation of hydrogen peroxide and thiobarbituric acid reactive substances in patients with community acquired pneumonia. Respir. Med. 2004; 98: 669-676. (Pubitemid 38949932)
7. Chan H.P., Tran V., Lewis C., Thomas P.S. Elevated levels of oxidative stress markers in exhaled breath condensate. J. Thorac. Oncol. 2009; 4: 172-178.
8. Ziȩba M., Nowak D., Suwalski M. i wsp. Enhanced lipid peroxidation in cancer tissue homogenates in non-small cell lung cancer. Monaldi. Arch. Chest Dis. 2001; 56: 110-114. (Pubitemid 32700589)
9. Weinberg F., Chandel N.S. Reactive oxygen species-dependent signaling regulates cancer. Cell. Mol. Life Sci. 2009; 66: 3663- -3673.
10. Swidzińska E., Naumnik W., Chyczewska E. Angiogeneza i neoangiogeneza - znacznie w raku płuca i innych nowotworach. Pneumonol. Alergol. Pol. 2006; 74: 414-420.
11. Carpini J.D., Karam A.K., Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010; 13: 43-58.
12. Vidal O., Metges J.P., Elizalde I. i wsp. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br. J. Surg. 2009; 96: 1443-1451.
13. Bendardaf R., Buhmeida A., Hilska M. i wsp. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2008; 28: 3865-3870.
14. Kaya A., Ciledag A., Gulbay B.E. i wsp. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir. Med. 2004; 98: 632-636. (Pubitemid 38949927)
15. Reck M., von Pawel J., Zatloukal P. i wsp. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 2009; 27: 1227-1234.
16. Munker M., Munker R., Saxton R.S., Hoeffler H.P. Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res. 1987; 47: 4081-4085. (Pubitemid 17108474)
17. Babbar N., Casero R.A. Tumor necrosis factor-a increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammationinduced carcinogenesis. Cancer Res. 2006; 66: 11125-11130. (Pubitemid 46009938)
18. 3- in breath condensate.Clin. Chim. Acta 2003; 335: 65-74. (Pubitemid 37338309)
19. Luczyńska M., Szkudlarek U., Dziankowska-Bartkowiak B. i wsp. Elevated exhalation of hydrogen peroxide in patients with systemic sclerosis. Eur. J. Clin. Invest. 2003; 33: 274-279. (Pubitemid 36411547)
20. 2 production by macrophages and neutrophils with homovanilic acid and horse-radish peroxidase. J. Immunol. Methods 1983; 63: 347-357. (Pubitemid 13018061)
21. Kietzmann D., Kahl R., Müller M., Burchardi H., Kettler D. Hydrogen peroxide in expired breath condensate of patients with acute respiratory failure and with ARDS. Intensive Care Med. 1993; 19: 78-81. (Pubitemid 23114204)
22. Faux S.P., Tai T., Thorne D., Xu Y., Breheny D., Gaca M. The role of oxidative stress in the biological responses of lung epithelial cells to cigarette smoke. Biomarkers 2009; 14: 90-96.
23. Yao H, Rahman I.(2009)Current concepts on the role of inflammation in COPD and lung cancer Curr. Opin. Pharmacol. 9:375-383
24. Nowak D., Ka?ucka S., Bia?asiewicz P., Król M. Exhalation of H2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. Free Radic. Biol. Med. 2001; 30: 178-186. (Pubitemid 32121795)
25. Rijneveld A.W., Florquin S., Branger J., Speelman P., Van Deventer S.J.H., van der Poll T. TNF-α compensates for the impaired host defense of Il-1 Type I receptor-deficient mice during pneumococcal pneumonia. J. Immunol. 2001; 167: 5240-5246. (Pubitemid 33009761)
26. Matanić D., Beg-Zec Z., Stojanović D., Matakorić N., Flego V., Milevoj-Ribić F. Cytokines in patients with lung cancer. Scand. J. Immunol. 2003; 57: 173-178. (Pubitemid 36232885)
27. Siziopikou K.P., Harris J.E., Casey L., Nawas Y., Braun D.P. Impaired tumoricidal function of alveolar macrophages from patients with non-small cell lung cancer. Cancer 1991; 68: 1035-1044.
28. Carpagnano G.E., Spanevello A., Curci C. i wsp. IL-2, TNFalpha, and leptin: local versus systemic concentrations in NSCLC patients. Oncol. Res. 2007; 16: 375-381. (Pubitemid 47413253)
29. Gessner C., Rechner B., Hammerschmidt S. i wsp. Angiogenic markers in breath condensate identify non-small cell lung cancer. Lung Cancer 2010; 68: 177-184.
30. Choi S.H., Park E.Y., Jung H.L. i wsp. Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion. J. Korean Med. Sci. 2006; 21: 608-613.
31. Brugarolas A., Takita H. Immunologic status in lung cancer. Chest 1973; 64: 427-430.
32. Nagata N., Nikaido Y., Kido M., Ishibashi T., Sueishi K. Terminal pulmonary infections in patients with lung cancer. Chest 1993; 103: 1739-1742. (Pubitemid 23174307)
33. Ziȩba M., Baranowska A., Krawczyk M., Noweta K., Grzelewska- Rzymowska I., Kwiatkowska S. Pneumonia as a cause of death in patients with lung cancer. Radiol. Oncol. 2003; 37: 167-174.